Rule one of looking at clinical data is to not take any free advice from Adam Feuerstein. Quite frankly, you should be wary of almost any steaming pile that TheStreet pushes out, but his are especially suspicious.
There is the risk of getting a notice to that effect if they do not file within the next 3 weeks, and then they will have about a month or two to get it in. Chances are that the quarterly report is less difficult than the annual..
Russia and Belarus have always had that ability, but you have to factor in that the entities from this geography tend to be less consistent in production and delivery than their Canadian counterparts, which is why they are able to sell the same product at a premium. It is a qualitative advantage.
It is usual for a smart large shareholder to stack the board with proven winners and trim it of those with whom confidence is lacking.
I believe Berkshire has to wait on increasing their position substantially as it could damage NOLs that USG has. Because of the incredible losses sustained at the bottom, USG has enough losses to use for the next few years, after which Berkshire will likely acquire the company. I think they cannot increase their position by more than 50% within a three year period without hitting the NOLs or something like that.
I think they will try to refinance some of their worst debt shortly, since rates have stayed low and they have made efforts to improve their default risk.
Well, insiders sell for many reasons. Sometimes they have to buy a car, or house, or pay for a child's tuition, or a mistress' apartment. Selling is less meaningful of an indicator than buying.
That is because each of these accounts is a network (closed or public) that handles hundreds to thousands of doctors writing prescriptions. Doctors are not accounts.
Was well into the market?
How many versions of generic renvela are actually available for sale in the EU, and from which manufacturers?
Your point is not relevant to the fact that an entity cannot get administrative approval by talking up recent clinical results, but rather solely through a formal and highly technical application process.
Maybe because a pharma cannot expand a label by taking up a clinical trial, but rather solely through the formal application process. The same question could have been asked about the US...why not talk it up to the FDA? Oh yeah, because that is asinine and could be harmful to the actual application process.